<DOC>
	<DOCNO>NCT01617213</DOCNO>
	<brief_summary>This trial determine feasibility efficacy lenalidomide maintenance therapy Multiple Myeloma patient treat dose intensive chemotherapy ( Melphalan 200 mg/m2 ) autologous PBSC transplant .</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation Maintenance Therapy Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Must 18 75 year age . ECOG performance status 0 , 1 2 . Patients history another malignant disorder eligible , provide receive active therapy 5 year . Patients basal cell squamous cell skin cancer eligible . Patients pregnant ineligible . Patients must furnish write informed consent HIPAA authorization release personal health information . Patients must able understand requirement study , abide study restriction , agree return require assessment . Patients must HIV HTLVI , II antibody seronegative . Patients must adequate visceral organ function Patients ineligible receive cumulative chemotherapy dose excess : carmustine ( BCNU ) 400 mg/m2 , cumulative anthracycline exposure excess 550 mg/m2 Adriamycin ( doxorubicin ) unless gatedpool radionuclide cardiac scan show great than/equal 45 % ejection fraction . Patients ineligible receive investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>